Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2019 San Antonio Breast Cancer Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Rugo on Updated Data From the SOPHIA Trial in HER2+ Metastatic Breast Cancer
Dr. Pinilla Alba on Safety Findings of the PARTNER Trial in Breast Cancer
Dr. Lin on Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer
Oncology Conference Articles
Margetuximab Plus Chemo Reveals Intriguing Benefit in HER2+ Breast Cancer
Hope S. Rugo, MD, FASCO, discusses the updated findings of the SOPHIA trial in HER2-positive metastatic breast cancer.
Murthy Shares Insight on HER2CLIMB Findings With Tucatinib in HER2+ Breast Cancer
Rashmi K. Murthy, MD, MBE, discusses the findings of the HER2CLIMB trial in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.
Piccart Highlights 6-Year Follow-Up With Adjuvant Pertuzumab Regimen in HER2+ Breast Cancer
Martine J. Piccart, MD, PhD, discusses the 6-year follow-up of the APHINITY trial and its impact on the breast cancer field.
Real-World Abemaciclib Use in MBC Is Heterogeneous
In the first 11 months following the FDA approval of the CDK4/6 inhibitor abemaciclib as a single agent and in combination with endocrine therapy for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer, it is being used heterogeneously, including in patients with characteristics indicative of worse prognosis.
Absolute Lymphocyte Count May Predict Eribulin Benefit in Breast Cancer
A high absolute lymphocyte count at baseline appears to be an independent predictor for longer overall survival in patients with metastatic breast cancer who are treated with eribulin mesylate.
Taxane Choice With Pertuzumab/Trastuzumab in HER2+ MBC Does Not Affect Outcome
The combination of pertuzumab and trastuzumab plus paclitaxel is commonly being used in the community for the treatment of patients with HER2-positive breast cancer, and appears to be as effective as pertuzumab and trastuzumab plus docetaxel according to real-world findings from a retrospective cohort study.
Analysis Unable to Achieve Concordance Among PD-L1 Assays in TNBC
Mathematical modeling was unable to harmonize the VENTANA SP263 and Dako 22C3 PD-L1 assays with the FDA-approved VENTANA PD-L1 SP142 companion diagnostic for the selection of patients with advanced triple-negative breast cancer appropriate for atezolizumab plus nab-paclitaxel.
Adjuvant Chemo Shows Slight Benefit in Younger Women With Breast Cancer Who Have Mixed Clinical, Genomic Risk
Patients with premenopausal breast cancer and discordant clinical and genomic risk had a small increase in distant metastasis if they did not receive adjuvant chemotherapy, according to a post hoc analysis of the MINDACT trial.
Neoadjuvant Olaparib Combo Safe in Breast Cancer
Adding the PARP inhibitor olaparib to neoadjuvant platinum based-chemotherapy was determined to be a safe treatment for patients with triple-negative breast cancer, as well as for patients with breast cancer whose tumors harbor germline
Chemo-Free Regimen Matches Neoadjuvant Chemo in HR+/HER2- Breast Cancer
Almost half of patients with high-risk luminal-B breast cancer converted to a low risk of recurrence following chemotherapy-free neoadjuvant therapy, matching the performance of standard chemotherapy in small randomized trial.
ctDNA and CTCs Potentially Poised to Predict Recurrence for Early TNBC
The presence of circulating tumor DNA and circulating tumor cells following neoadjuvant chemotherapy can be an independent predictor of disease recurrence in patients with early triple-negative breast cancer.
Residual Cancer Burden Predicts Patient Outcomes Across Breast Cancer Subtypes
Residual cancer burden after neoadjuvant chemotherapy has been shown to be an accurate long-term predictor of disease recurrence and survival across all breast cancer subtypes.
Adjuvant T-DM1 Benefit in HER2+ Breast Cancer Observed Across Key Subgroups
The invasive disease-free survival benefit with adjuvant T-DM1 versus trastuzumab in patients with HER2-positive early breast cancer who had residual invasive disease following neoadjuvant therapy was observed regardless of the type of neoadjuvant chemotherapy used.
Oral Regimen for Paclitaxel Administration May Become Available in Breast Cancer
The addition of encequidar (HM30181A) to oral paclitaxel is the first oral taxane regimen to result in an improvement in overall response rates as compared with an intravenous administration of paclitaxel in patients with metastatic breast cancer.
Estrogen Decreases Breast Cancer Incidence in Postmenopausal Women, Estrogen Plus Progestin Has Opposite Effect
Estrogen alone as menopausal hormone therapy was found to decrease breast cancer incidence in postmenopausal women.
Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab Proves Noninferiority Versus IV Drugs
A subcutaneous fixed-dose combination of pertuzumab and trastuzumab demonstrated noninferiority to intravenous formulations of the 2 drugs with respect to pharmacokinetics, clinical activity, and safety, a randomized trial demonstrated.
Further Data Demonstrate Equivalence for Subcutaneous, IV Formulations of Trastuzumab in HER2+ Breast Cancer
Subcutaneous trastuzumab with hyaluronidase-oysk in combination with intravenous pertuzumab and chemotherapy had a safety profile consistent with IV trastuzumab in first-line metastatic HER2-positive breast cancer treatment.
Neoadjuvant Durvalumab Regimen Shows Promise in TNBC
A durvalumab-based neoadjuvant regimen induced an impressive pathologic complete response rate in patients with triple-negative breast cancer.
Accelerated Partial Breast Irradiation Could Replace Whole Breast Irradiation in Low-Risk Early Breast Cancer
Accelerated partial breast irradiation using intensity-modulated radiotherapy is not significantly different from whole breast irradiation in preventing recurrence in patients with low-risk early breast cancer.
Extended Follow-Up Shows Continued Olaparib Benefit in BRCA+ MBC
Olaparib continued to show a numerical overall survival (OS) benefit with a favorable hazard ratio for OS versus chemotherapy in patients with
-positive, HER2-negative metastatic breast cancer, according to an extended, exploratory follow-up analysis of the phase III OlympiAD trial.
Dual Anti-HER2 Therapy Reduces Recurrence Risk
A pathologic complete response to HER2-directed neoadjuvant therapy reduced the risk of recurrence in early HER2-positive breast cancer but did not eliminate it, supporting the common practice of continued anti-HER2 therapy.
Neoadjuvant Atezolizumab Regimen Slightly Improves pCR in TNBC
Atezolizumab (Tecentriq) in combination with carboplatin and nab-paclitaxel (Abraxane) did not lead to a statistically significant increase in pathologic complete response (pCR) rate compared with carboplatin/nab-paclitaxel alone in patients with early high-risk and locally advanced triple-negative breast cancer,
Survival Benefit Hinted at With Durvalumab Maintenance in TNBC
Maintenance durvalumab may improve outcomes versus chemotherapy in patients with triple-negative breast cancer or those with PD-L1–positive breast cancer across several subtypes, according to exploratory analyses from the phase II randomized SAFIR02-IMMUNO trial presented at the 2019 San Antonio Breast Cancer Symposium.
Anastrozole Maintains Breast Cancer Prevention Effect in Long-Term Follow-Up
The aromatase inhibitor anastrozole maintained a preventive effect for postmenopausal women at high risk for breast cancer nearly 12 years after discontinuing treatment.
Benefit in pCR Rates Are Achieved With Pembrolizumab in Early TNBC
Patients with triple-negative breast cancer have greater rates of pathologic complete responses when pembrolizumab is added to neoadjuvant and adjuvant chemotherapy. Furthermore, these benefits are observed across patient subgroups, most notably in those patients with stage III and/or node-positive disease.
Palbociclib Real-World Results Indicate OS Benefit in Frontline HR+/HER2- Breast Cancer
Real-world data for frontline palbociclib indicate that the positive progression-free survival data observed with the CDK4/6 inhibitor in the pivotal PALOMA-2 trial would likely translate to an overall survival benefit in patients with HR-positive/HER2-negative metastatic breast cancer
Adjuvant T-DM1 for Early HER2+ Breast Cancer Demonstrates Low Recurrence Rate
The first reported data for adjuvant ado-trastuzumab emtansine in early HER2-positive breast cancer showed high rates of disease control in a randomized trial designed to compare toxicities with trastuzumab and paclitaxel.
Margetuximab Update Elucidates Clinical Benefit in HER2+ Metastatic Breast Cancer
Margetuximab continued to show a clear progression-free survival benefit and a trend toward an overall survival benefit versus trastuzumab (Herceptin) when either agent was combined with chemotherapy in patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies.
Adjuvant Pertuzumab Regimen Shows Modest OS Benefit in HER2+ Early Breast Cancer
Adjuvant pertuzumab (Perjeta) with trastuzumab (Herceptin) plus chemotherapy showed a 0.9% improvement in overall survival and continued to reduce the risk of disease recurrence in patients with HER2-positive early breast cancer.
Tucatinib Boosts Survival in HER2+ Breast Cancer, FDA Submission Imminent
Adding tucatinib to trastuzumab (Herceptin) and capecitabine (Xeloda) reduced the risk of death by 34% in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.
S-1 Improves iDFS in HR+, HER2- Breast Cancer
Adding the novel oral fluoropyrimidine derivative S-1 to adjuvant endocrine therapy significantly improved invasive disease-free survival for Japanese patients with HR-positive, HER2-negative breast cancer.
T-DXd Shows Potential to Establish New Standard of Care in Advanced HER2+ Breast Cancer
Trastuzumab deruxtecan (T-DXd; DS-8201) induced a confirmed objective response rate of almost 61% and a durable benefit in heavily pretreated patients with advanced HER2-positive breast cancer.
ASCO GU 2020: Dr. Taplin Highlights Ongoing Research in Prostate Cancer
Dr. Lonial on the Role of Targeted Therapy in AML and ALL
RET-Fusion NSCLC Treatments LOXO-292 & BLU-667
Hematopoietic Stem Cell Transplant: A Viable Option for Older Patients With AML
Dr. Grivas on the Role of Targeted Therapy in Prostate Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.